大剂量环磷酰胺冲击疗法对难治性肾病综合征的疗效观察
- 格式:pdf
- 大小:194.04 KB
- 文档页数:2


大剂量环磷酰胺治疗肾病综合征的分析赵志敏发表时间:2018-05-09T14:32:17.960Z 来源:《医师在线》2018年1月上第1期作者:赵志敏[导读] 肾病综合征是临床比较常见的疾病,治疗比较复杂,没有统一的治疗方案。
黑龙江省双鸭山市人民医院 155100【摘要】目的:探讨大剂量环磷酰胺治疗肾病综合征的疗效。
方法:选择2016年10月至2017年2月来我院就诊的152例肾病综合征临床资料,其中包括难治性89例和非难治性63例,入院后给予大剂量环磷酰胺冲击治疗,并观察分析其疗效。
结果:难治性肾病综合征患者中治愈59例、好转18例、无效12例,有效率为86.5%;非难治性肾病综合征患者中治愈46例、好转10例、无效7例,有效率为88.9%;总有效率为87.5%。
结论:大剂量环磷酰胺治疗肾病综合征安全快速有效,值得临床广泛应用。
【关键词】大剂量环磷酰胺肾病综合征??????? 肾病综合征是临床比较常见的疾病,治疗比较复杂,没有统一的治疗方案。
难治性肾病综合征一般是指对常规激素治疗效果不良的肾病综合征,包括[1]:①依赖型(激素治疗有效果但无法减量);②复发型(6个月内复发1次以上或者1年内复发2次以上);③无效型(最初激素治疗无效或者复发后再次激素治疗无效)。
本文选择难治性肾病综合征患者和非难治性肾病综合征患者,均采用大剂量环磷酰胺冲击治疗,观察分析治疗效果。
现报告如下:??????? 1、资料与方法??????? 1.1 临床资料??????? 选择2016年10月至2017年12月来我院就诊的152例肾病综合征临床资料,其中包括难治性89例(依赖型30例、复发型32例、无效型27例)和非难治性63例。
所有患者中男性82例,女性70例;年龄23~61岁,平均年龄38.23±6.75岁;病程3~72个月,平均病程9.34±3.28个月。
所有临床资料均符合肾病综合征的诊断标准[2],并排除引起肾病综合征的其它原因和不适合环磷酰胺治疗的因素。
DOI:10.19368/ki.2096-1782.2023.14.066分析环磷酰胺冲击疗法治疗小儿肾病综合征的疗效及对肾功能的影响朱国琴,张林,赵丽萍无锡市儿童医院肾脏风湿免疫科,江苏无锡214000[摘要]目的评估小儿肾病综合征行环磷酰胺冲击治疗的效果。
方法选取2018年1月—2022年11月无锡市儿童医院收治的82例小儿肾病综合征患儿为研究对象,采用单双数分为两组,每组41例。
一般组方案为甲泼尼龙治疗,治疗组方案为环磷酰胺冲击治疗。
比较两组肾功能、肝功能指标、缓解率、不良反应发生率。
结果治疗后,治疗组24 h尿蛋白定量、血肌酐水平均低于一般组,差异有统计学意义(P<0.05)。
治疗后,治疗组白蛋白、总蛋白水平均高于一般组,差异有统计学意义(P<0.05)。
治疗组缓解率为97.56%,高于一般组,差异有统计学意义(χ2=4.986,P<0.05)。
治疗组不良反应发生率为4.88%,明显低于一般组,差异有统计学意义(χ2=8.022,P<0.05)。
结论环磷酰胺冲击疗法不良反应少,对肾功能有改善作用,还能减轻肝脏损伤,提高小儿肾病综合征缓解率。
[关键词]环磷酰胺;远期疗效;肾病综合征;不良反应;冲击疗法[中图分类号]R4 [文献标识码]A [文章编号]2096-1782(2023)07(b)-0066-04Analysis of the Efficacy of Cyclophosphamide Pulse Therapy in the Treat⁃ment of Nephrotic Syndrome in Children and Its Impact on Renal Function ZHU Guoqin, ZHANG Lin, ZHAO LipingDepartment of Renal Rheumatology and Immunology, Wuxi Children's Hospital, Wuxi, Jiangsu Province, 214000 China[Abstract] Objective To evaluate the effect of cyclophosphamide pulse therapy in children with nephrotic syndrome.Methods A total of 82 children with nephrotic syndrome treated in Wuxi Children's Hospital from January 2018 to November 2022 were selected as the study objects, and were divided into two groups by using odd and even numbers, with 41 cases in each group. The general group was methylprednisolone therapy and the treatment group was cyclo‐phosphamide shock therapy. Renal function, liver function indexes, remission rate and incidence of adverse reactions were compared between the two groups. Results After treatment, 24 h urinary protein quantity and serum creatinine level in the treatment group were lower than those in the general group, and the differences were statistically signifi‐cant (P<0.05). After treatment, albumin and total protein levels in the treatment group were higher than those in the general group, and the difference was statistically significant (P<0.05). The remission rate of the treatment group was 97.56%, which was higher than that of the general group, and the difference was statistically significant (χ2=4.986, P< 0.05). The incidence of adverse reactions in the treatment group was 4.88%, which was significantly lower than that in the general group, and the differences were statistically significant (χ2=8.022, P<0.05). Conclusion Cyclophospha‐mide impact therapy has less adverse reactions, can improve renal function, reduce liver damage, and increase the re‐mission rate of nephrotic syndrome in children.[Key words] Cyclophosphamide; Long-term efficacy; Nephrotic syndrome; Adverse reactions; Pulse therapy肾病综合征在各类肾病病变中约有20%的占比,此病会刺激肾小球基底膜,增强其通透性,常引[作者简介] 朱国琴(1980-),女,硕士,主治医师,研究方向为肾脏风湿免疫。